Onco Actu du 20 mai 2016

	2.6 Etiologie - Environnement
EU delays vote on weed-killer glyphosate license amid cancer row [Reuters] EU sources said the vote was postponed due to opposition in France and Germany, which have big farming and chemicals industries.
	3. Prévention
Can Most Cancer Really Be Prevented? [TIME] A new study zeroes in on an answer.
	3.1 Tabac
Tobacco packs changed forever as the UK introduces plain packaging laws [Cancer Research UK] The United Kingdom and France today join Australia as the first countries in the world to introduce similar laws. Australia’s legislation took effect in December 2012.
Plain cigarette packaging has arrived, but will it reduce smoking? [The Guardian] Quantifying the expected impact of standardised packaging on actual behaviour when implemented in the real world is difficult.
Tobacco firms lose high court battle over plain packaging [The Guardian] Plain packaging of cigarettes will be mandatory from Friday after the high court in London rejected an attempt by the tobacco industry to prevent the change in the law.
	3.8 Prévention - Alimentation
Why ‘healthy’ food is a bankrupt concept [STAT] Frankly, the word “healthy” has been bandied about so much it’s become bankrupt. Applying it to food doesn’t even make sense. That’s because it’s not food that’s healthy: It’s us, as long as we eat food that is nutritious or nourishing. Those are two terms I’d like to restore to our lexicon.
	4.10 Dép., diag. & prono. - Poumon
Lung cancer breathalyzer in UK clinical trials [Reuters] Boyle said their sensors were originally developed for detecting explosives and toxic gases but were re-programmed to identify the chemical markers of diseases, with a lung cancer breathalyzer the first to reach clinical trial.
	4.2 Dép., diag. & prono. - Génome
Myriad Announces Plans to Launch a Web Portal for Patients that Will Provide Access to Test Results, Tools and Health Information [Myriad] Myriad anticipates that the first phase of the portal will be available by the end of the quarter.
	4.8 Dép., diag. & prono. - Droit
Myriad Genetics' Statement on HIPAA Complaint from Four Patients [Myriad] "Genetic information is more indelible than your social security number, bank account number or passport number, so we are committed to acting responsibly in the public's interest," said Marsh. "Privacy is fundamentally about trust, and Myriad respects every patient's right to protect his or her own health information."
Patients challenge Myriad Genetics for access to their gene data [STAT] Myriad spokesman Ron Rogers said Myriad patients will receive their full genetic information upon request.
After a prominent gene-testing firm declined to give patients their complete data, ACLU filed a legal complaint [Science] Is there a broader goal to pressure Myriad into depositing its data into public databases like ClinVar?
Myriad hit with complaint over access to genetic information [Reuters] Sandra Park, an attorney with the ACLU, said the organization was pushing ahead with the complaint even though Myriad gave the patients the information late on Wednesday. Park said the group wants to seek a determination that patients have a right to all their genetic information.
	5.10 Traitements - Essais
Better with bitcoin [The Economist] Blockchain technology could improve the reliability of medical trials.
	5.12 Immunothérapies
Cancer can be combated with reprogrammed macrophage cells [Karolinska Institutet] Researchers at Karolinska Institutet have generated antibodies that reprogramme a type of macrophage cell in the tumour, making the immune system better able to recognise and kill tumour cells.
	5.2 Pharma
Viehbacher, Germano--Epstein? Big Pharma execs, and the call of biotech [FierceBiotech] Epstein was formerly head of Novartis Oncology and has a bachelor’s degree in pharmacy, as well as the necessary MBA. In fact, while leading Novartis Oncology, the drugmaker itself notes that he built this business from “startup to number two in the world through six new drug approvals and more than 10 indication expansions.”
Phase III study of Roche’s Alecensa (alectinib) showed superior efficacy versus crizotinib in Japanese people with a specific type of lung cancer [Roche] First investigational head-to-head study of Alecensa versus crizotinib in people with advanced ALK-positive non-small cell lung cancer (NSCLC).
	5.2.3 Pharma - économie
The Real Reason Big Pharma Wants to Help Pay for Your Prescription [Bloomberg] A billion-dollar system in which charitable giving is profitable.
	5.4 Traitements - Economie
ARIAD Announces Pricing and Reimbursement for Iclusig in France [ARIAD] As a result, ARIAD will record net product revenue related to cumulative shipments in France of approximately $25 million in the second quarter of 2016.
Vermont poised to become first state to require pharma to justify pricing [STAT] The bill would require state officials to identify 15 drugs for which “significant health care dollars” are spent, and where list prices rose by 50 percent or more over the previous five-year period.
Long term benefits of breast cancer drug pertuzumab too uncertain says NICE in draft guidance [NICE] NICE has today issued draft guidance not recommending pertuzumab (Perjeta, Roche Products) to treat HER2-positive breast cancer because it is uncertain how the responses to treatment seen in the clinical trials translate into long term benefits for patients.
Breast cancer drug rejected despite doubling in tumour destruction [The Telegraph] Baroness Delyth Morgan, chief executive at Breast Cancer Now, said: "This is a disappointing but not unexpected decision. Perjeta before surgery has shown some promising early results, and could benefit up to 15 per cent of breast cancer patients, but the clinical evidence is still insufficient."
Roche breast cancer drug Perjeta rejected by UK cost agency [Reuters] "In order to be able to recommend pertuzumab as an addition to trastuzumab and chemotherapy, the committee needed to have more evidence of its long-term clinical benefits, particularly its impact on overall survival," said Andrew Dillon, NICE chief executive.
	5.5.1 ASCO (général)
Moving Ahead In Cancer Care: 2016 ASCO Annual Meeting [The OBR Blog] The theme of the meeting is Collective Wisdom: The Future of Patient-Centered Care and Research. Five studies selected from the 5,200 abstracts submitted to ASCO were featured at a pre-meeting press cast.
	5.5.1.1 ASCO (général) - Industriels
8 Stocks on the Move After ASCO Cancer Abstracts [24/7 Wall St.] From a competitive standpoint, Credit Suisse continues to favor Bristol-Myers Squibb Co. and Rogers Corp., but is eager to see credit given to Eli Lilly and Co. for abemaciclib and Pfizer Inc. for avelumab.
Clovis Oncology Announces Data Presentations at 2016 ASCO Annual Meeting [Clovis] New rucaparib data to be highlighted in poster presentations.
	5.5.4 ASCO (immunothérapies)
Merck's Keytruda shines in pre-ASCO abstract release, with Pfizer catching the limelight, too [FiercePharma] The ASCO abstracts are out, and they’re a mixed bag for the Big Pharma companies tied up in the PD-1/PD-L1 race.
	5.5.7 ASCO (gynéco)
ImmunoGen Reports Efficacy and Safety Data from a 46-Patient Cohort of Mirvetuximab Soravtansine in FRα-Positive Ovarian Cancer [ImmunoGen] Confirmed objective response rate of 44% and median progression-free survival of 6.7 months seen in cohort subset mirroring patient population selected for planned Phase 3 study.
	6.1 Observation
Overweight Colorectal Cancer Patients Have Higher Survival Rate Than Normal-Weight Patients [Kaiser Permanente] Kaiser Permanente study adds to growing body of research about ‘obesity paradox’.
Global life expectancy increases to 71.4 years [The Guardian] Life expectancy across the globe has increased by five years since 2000, the fastest rise in lifespans since the 1960s, according to the World Health Organisation (WHO).
	6.10 Politiques
New U.S. overtime rules will bump up postdoc pay, but could hurt research budgets [Science] Although welcomed by many, the change could have major impacts on budgets of labs and universities, which have only until 1 December to comply.
Postdoc pay to increase due to new overtime rule [Science] The long-awaited new rule requires that employers provide overtime pay of time and a half for work over 40 hours per week to professional employees who earn less than $913 a week or $47,476 a year, with certain exceptions. (The previous threshold was $23,660 a year.)
US law could increase postdoc pay — and shake up research system [Nature News & Comment] The law may ultimately mean fewer postdocs. But some say that the policy could spark much-needed changes to a research system that relies heavily on postdocs yet offers them few opportunities for career advancement.
	6.6 Publications
Retractions aren’t enough: Why science has bigger problems [Retraction Watch] Whatever the vast majority of retractions are, they’re a tiny fraction of the number of papers that are just wrong — by which I mean they present no good empirical evidence for their claims.